Marinus Pharmaceuticals to Present at the Oppenheimer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Marinus Pharmaceuticals to Present at the Oppenheimer Healthcare Conference

RADNOR, Pa., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS ), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, today announced that Christopher M. Cashman, Chairman and Chief Executive Officer of Marinus, will present at the 2014 Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 9:10 a.m. ET. The conference will take place at the Crowne Plaza Hotel in New York. 

The Company's presentation will be available via a live webcast. To access the live audio webcast, please logon through the link located in the Investors section of the Marinus website at www.marinuspharma.com under the Events & Presentations tab. 

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. The Company's clinical stage drug candidate, ganaxolone, is a novel synthetic analog of the endogenous neurosteroid, allopregnanolone. Ganaxolone is known for its anticonvulsive and antianxiety effects, and was designed to avoid hormonal side-effects associated with endogenous neurosteroids. Ganaxolone is presently being studied in a multinational, randomized, placebo-controlled, Phase 3 clinical trial in adult subjects for adjunctive treatment of partial-onset seizures. The Company currently has a Phase 2 proof-of-concept pediatric clinical trial in progress for ganaxolone as a treatment for behaviors in Fragile X Syndrome and is initiating a Phase 2 proof-of-concept clinical study later this year for the treatment of PCDH19 female pediatric epilepsy. Both Fragile X Syndrome and PCDH19 female pediatric epilepsy are potential orphan disorders that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA A receptors. For additional information, please visit the Company's website at www.marinuspharma.com .

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Words such as "may", "will", "expect", "anticipate", "estimate", "intend", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements.  Examples of forward looking statements contained in this press release include, among others, statements regarding our expectations regarding our development plans for our product candidate, including optimizing a product's formulation and the clinical trial testing schedule. Forward-looking statements in this release involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements.  Such risks and uncertainties include, among others, the uncertainties inherent in the conduct of future clinical trials, the timing of the clinical trials, enrollment in clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters, including the development of formulations of ganaxolone, that could affect the availability or commercial potential of our drug candidates.  Marinus undertakes no obligation to update or revise any forward-looking statements.  For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see filings Marinus has made with the Securities and Exchange Commission.

Lisa M. Caperelli Senior Director, Investor Relations & Corporate Communications Marinus Pharmaceuticals, Inc. 484-801-4674

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Palm Beach Loan Company Tests Luxury Lending Demand

Updated Category News Views 68

Jewelry in a safe is dead capital until somebody lends against it. That plain fact sits behind Luxury Asset Capital's latest move: the launch of Palm Beach Loan Company, a South Florida brand aimed at wealthy owners of watches, diamonds, art, handbags, gold, collectibles, and other high-value possessions. The company is not asking clients to sell the stuff they spent...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 63

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 186

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
Linux Foundation Unveils the Global Fraud Alliance

Updated Category News Views 48

Who would have thought the tech wizards at the Linux Foundation would step up to tackle fraud on a global scale? That's what we've got with their latest play: the Open Financial Trust Alliance (OFTA). Launched at the Singapore FinTech Festival, they've got their sights on connecting the world's disconnected fraud fight. Think of it as a translator for the tangled mess of...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 164

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Utility Global’s India Steel Move Needs Hard Numbers

Updated Category News Views 38

Steel decarbonization announcements can sound enormous before a single bolt gets tightened. Utility Global says it plans to deploy its first industrial H2Gen project in India with Tata Steel, and that is plainly worth watching. Tata Steel is a serious industrial name, India is a consequential steel market, and any technology that can credibly lower emissions from heavy...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 37

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading
Auria, LSAS Team Up: Japan Space Frontier Beckons

Updated Category News Views 105

Pioneering Ventures in Japan's Space Race Watch out, folks—Auria and LSAS Tec have something cooking. One's a titan in space technology, and the other's a maestro in mission analysis. They're joining forces to tango in Japan's booming space market. If you're into the street-smart equity dance, this partnership ain't just chatter over coffee; it's a leap toward new...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 71

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading

Top 5 Most Recently Viewed Articles

MPE Partners Invests in SKB Cases to Enhance Growth Potential

Updated Category News Views 369

MPE Partners Makes Strategic Investment in SKB Cases MPE Partners, also known as Morgenthaler Private Equity, has announced an exciting investment in SKB Cases, a prominent manufacturer known for its specialty protective cases. With a robust customer base exceeding 2,000 clients across military, industrial, music, and pro AV sectors, this strategic move is set to...

Continue Reading
Aspire Expands into Europe with EU EMI License and Hub Establishment

Updated Category News Views 186

Aspire Expands into Europe with EU EMI License Aspire, a leading global fintech firm based in Singapore, recently announced a significant breakthrough by acquiring its Electronic Money Institution (EMI) license. This important approval lays the groundwork for its operations in the Netherlands, marking the company's formal entry into the European Union. Milestone for...

Continue Reading
GOTS Combats Greenwashing with Consumer Education Campaign

Updated Category News Views 128

GOTS Takes Action Against Greenwashing The Global Organic Textile Standard (GOTS) is excited to announce the return of its #BehindTheSeams campaign, which aims to raise awareness about the sustainable features of GOTS-certified products. This year's campaign will run throughout September, expanding its efforts to educate consumers about the sustainable practices behind...

Continue Reading
Advancements in Cancer Treatment: Insights from Indaptus Therapeutics

Updated Category News Views 123

Exciting Clinical Developments by Indaptus Therapeutics Indaptus Therapeutics, Inc. (Nasdaq: INDP) is making significant strides in the realm of cancer therapy, focusing on innovative treatments for complex conditions such as urothelial cancer. Their ongoing clinical trial, labeled INDP-D101, has revealed promising results regarding their Decoy20 monotherapy. Recently, a...

Continue Reading
Dr. Réjean Boivin Appointed as Editor-in-Chief of Journal

Updated Category News Views 474

Dr. Réjean Boivin Takes the Helm at Review of Scientific Instruments AIP Publishing is excited to welcome Dr. Réjean Boivin as the new editor-in-chief for Review of Scientific Instruments. Boivin, who previously directed the Center of Excellence for Advanced Diagnostics at General Atomics, is a well-respected figure in the field, having held various roles such as...

Continue Reading